These genes were associated with anti-tumor characteristics of lymphocytes and myeloid cells, as well as the activation of ECs by TNF and interleukins, which had been reported previously.30 Both angiogenic and pro-immunity features of ECs emerging in parallel complicate the interpretation of the effect of RCT on the EC populations, indicating that further studies should focus on inhibiting the pro-angiogenic side of ECs while aiming to preserve their inflammatory features during therapy. The gene discussed is TNF; the disease is neoplasm.